Your session is about to expire
← Back to Search
XmAb23104 + Ipilimumab for Solid Tumors (DUET-3 Trial)
DUET-3 Trial Summary
This trial is testing a new drug, XmAb23104, to see if it is safe and effective at treating advanced solid tumors.
DUET-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDUET-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DUET-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not taken antibiotics or received a live-virus vaccine recently.I have an advanced solid tumor confirmed by a lab test.I have not taken certain medications within specific timeframes.I have colorectal cancer with MSS or proficient mismatch repair, measurable disease, and a life expectancy over 3 months.I am fully active and can carry on all my pre-disease activities without restriction.I have not taken ipilimumab in the last 4 weeks.I have an advanced solid tumor and have undergone standard treatment for it.You have not received treatment with an experimental anti-ICOS therapy before.You are currently receiving other treatments for cancer.
- Group 1: XmAb®23104 Combination Therapy with Ipilimumab
- Group 2: XmAb®23104 Monotherapy
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other scientific endeavors have investigated XmAb®23104?
"Currently, there are 318 ongoing clinical trials for XmAb®23104 with 38 studies in their final stage. Most of the research sites are based out of Pittsburgh, Pennsylvania - but a total of 20362 locations all around the world have been approved to administer this medication."
How many participants are currently partaking in this experiment?
"For this experiment to be successful, 234 participants meeting the inclusionary criteria must partake. ICON plc is funding and managing this trial through various medical centres such as University of Michigan in Ann Arbor, MI and University of Iowa Hospital & Clinics at Iowa City, IA."
Has XmAb®23104 been granted authorization from the FDA?
"Our team evaluated the safety of XmAb®23104 on a 1-3 scale and gave it a score of 1. This is because this Phase 1 trial has minimal data to support its efficacy and safety."
Are there still vacancies available for participation in this clinical trial?
"Confirmed. The research hosted on clinicaltrials.gov confirms that this medical study, which was initially posted in May 1st 2019, is actively recruiting participants. A total of 234 patients need to be enrolled from 16 distinct sites."
What indications is XmAb®23104 regularly prescribed to treat?
"XmAb®23104 is mainly employed to treat cutaneous melanoma, yet can also assist with complete resection, liver carcinoma, and metastatic melanoma."
Share this study with friends
Copy Link
Messenger